NSEUpdates3 Aug 2026 · 3 Aug 2026, 05:36 pm

Updates

Piramal Pharma Limited · PPLPHARMA

✦ AI SummaryRegulatory

Piramal Pharma Limited has resumed operations at its facilities in Ahmedabad, Gujarat, after a temporary suspension due to heavy rainfall and flooding. The company has completed a preliminary assessment and initiated the insurance claim process, with no material impact expected on its operations or financial performance.

Analysis Scores

Earnings Impact5/10
Growth Catalyst2/10
Governance Concern1/10
Regulatory Risk8/10
Balance Sheet Risk3/10
Liquidity Impact8/10
Market Sentiment5/10

✦ Ask a Question

Ask anything about this announcement — AI will answer based on the filing content.

0/500

Full Announcement

Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 Resumption of operations at Company s facilities located at Ahmedabad, Gujarat

Attachments (1)

📄

PIRAMALPHARMA_03082026173517_Reg_30_Intimation_-_Resumption_of_operation.pdf

pdf

Download →
View document text
3rd August, 2026 BSE Limited National Stock Exchange of India Limited P.J. Towers, Dalal Street, Fort, Exchange Plaza, Bandra-Kurla Complex, Mumbai- 400 001 Bandra (East), Mumbai – 400 051 BSE scrip code: 543635 NSE symbol: PPLPHARMA Sub: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 – Resumption of operations at Company’s facilities located at Ahmedabad, Gujarat Dear Sir / Madam, This is further to our communication dated 24th July, 2026, regarding temporary suspension of operations at the Company's manufacturing facilities located at Plot Nos. 18 and 19 – PHARMEZ - Pharmaceutical Special Economic Zone, Village Matoda, Sarkhej Bawla, NH 8A, Taluka Sanand, Ahmedabad - 382 213, Gujarat, India, due to exceptionally heavy rainfall and flooding across parts of Gujarat. We wish to inform you that operations have resumed across substantially all areas of the aforesaid facilities, with only limited restoration and recommissioning activities ongoing in certain sections. The Company has completed a preliminary assessment of the impact on its assets and operations and has initiated the insurance claim process. Based on the assessment undertaken to date, the Company does not expect any material impact on its operations or financial performance. This is for your information and records Thank you. Yours truly, For Piramal Pharma Limited Maneesh Sharma Company Secretary & Compliance Officer Piramal Pharma Limited CIN: L24297MH2020PLC338592 Registered Office: Ananta Building, Piramal Corporate Park, Opp. Fire Brigade, Kamani Junction, LBS Marg, Kurla (West), Mumbai – 400070, Maharashtra, India Tel No. +91 22 3802 3000 / 4000; Email Id: shareholders.ppl@piramal.com www.piramalpharma.com